ClinicalTrials.gov
public full text
Public Domain
Anti-SARS Cov-2 T Cell Infusions for COVID 19
This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high risk of requiring mechanical ventilation. The SARS-CoVSTs lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. These cell lines were frozen for later use and will be thawed and used to treat patients who meet the eligibility criteria.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Editorial: Deciphering the T cell response in SARS-CoV-2 infection#250590
- Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)#828255
- CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients#861950
- Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection#892258
- SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)#1046506
Record · ID 968207
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive